Cara Therapeutics マネジメント

マネジメント基準チェック /24

Cara Therapeuticsの CEO はChris Posnerで、 Nov2021年に任命され、の在任期間は 6.25年です。の年間総報酬は$ 2.92Mで、 24.9%給与と75.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.22%を直接所有しており、その価値は€ 34.96K 。経営陣と取締役会の平均在任期間はそれぞれ3年と5.3年です。

主要情報

Chris Posner

最高経営責任者

US$2.9m

報酬総額

CEO給与比率	24.9%
CEO在任期間	3yrs
CEOの所有権	0.2%
経営陣の平均在職期間	3yrs
取締役会の平均在任期間	5.3yrs

経営陣の近況

Recent updates

CEO報酬分析

Cara Therapeutics の収益と比較して、Chris Posner の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$96m
Jun 30 2024	n/a	n/a	-US$111m
Mar 31 2024	n/a	n/a	-US$123m
Dec 31 2023	US$3m	US$728k	-US$119m
Sep 30 2023	n/a	n/a	-US$117m
Jun 30 2023	n/a	n/a	-US$112m
Mar 31 2023	n/a	n/a	-US$84m
Dec 31 2022	US$3m	US$700k	-US$85m
Sep 30 2022	n/a	n/a	-US$89m
Jun 30 2022	n/a	n/a	-US$66m
Mar 31 2022	n/a	n/a	-US$93m
Dec 31 2021	US$10m	US$116k	-US$88m
Sep 30 2021	n/a	n/a	US$24m
Jun 30 2021	n/a	n/a	US$8m
Mar 31 2021	n/a	n/a	US$14m
Dec 31 2020	US$280k	n/a	US$8m
Sep 30 2020	n/a	n/a	-US$99m
Jun 30 2020	n/a	n/a	-US$115m
Mar 31 2020	n/a	n/a	-US$113m
Dec 31 2019	US$302k	n/a	-US$106m
Sep 30 2019	n/a	n/a	-US$98m
Jun 30 2019	n/a	n/a	-US$85m
Mar 31 2019	n/a	n/a	-US$79m
Dec 31 2018	US$494k	n/a	-US$74m

報酬と市場: Chrisの総報酬 ($USD 2.92M ) は、 German市場 ($USD 472.15K ) の同規模の企業の平均を上回っています。

報酬と収益: Chrisの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Chris Posner (54 yo)

3yrs

在職期間

US$2,922,469

報酬

Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Christopher Posner	President	3yrs	US$2.92m	0.22% € 35.0k
Ryan Maynard	Chief Financial Officer	2.2yrs	US$1.24m	0.015% € 2.3k
Derek Chalmers	Co-Founder & Senior Advisor	3yrs	US$10.20m	データなし
Scott Terrillion	Chief Compliance Officer	8yrs	US$1.59m	0.15% € 23.7k
Matthew Murphy	Manager of Investor Relations	no data	データなし	データなし

3.0yrs

平均在職期間

57.5yo

平均年齢

経験豊富な経営陣: 69Cの経営陣は経験豊富であると考えられます ( 3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Christopher Posner	President	6.3yrs	US$2.92m	0.22% € 35.0k
Martin Vogelbaum	Independent Chairman & Lead Independent Director	14.3yrs	US$519.99k	0.20% € 31.9k
Graeme Milligan	Member of the Scientific Advisory Board	no data	データなし	データなし
Stanley Watson	Member of the Scientific Advisory Board	no data	データなし	データなし
James Kauer	Member of the Scientific Advisory Board	no data	データなし	データなし
Philip Portoghese	Member of the Scientific Advisory Board	no data	データなし	データなし
Jeffrey L. Ives	Independent Director	10.3yrs	US$272.49k	0.087% € 13.9k
Helen Boudreau	Independent Director	1.3yrs	US$376.01k	0% € 0
Susan Shiff	Independent Director	4.4yrs	US$262.49k	0.094% € 15.0k
Lisa von Moltke	Independent Director	2yrs	US$254.99k	0.059% € 9.4k

5.3yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: 69Cの取締役会は経験豊富であると考えられます ( 5.3年の平均在任期間)。

Cara Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

Cara Therapeutics, Inc. Appoints Helen M. Boudreau to Board of Directors

Cara Therapeutics Announces Appointment of Lisa Von Moltke, M.D., to Its Board of Directors

Key Executive recently sold €111k worth of stock

Cara Therapeutics, Inc Appoints Ryan Maynard as Principal Financial Officer and Principal Accounting Officer

Recent updates

Cara Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement under Nasdaq Listing Rule 5550(b)(1)

Third quarter 2024 earnings released: US$0.23 loss per share (vs US$0.52 loss in 3Q 2023)

New major risk - Financial position

Second quarter 2024 earnings released: US$0.37 loss per share (vs US$0.58 loss in 2Q 2023)

Nasdaq Grants Cara Therapeutics Additional 180 Days to Regain Compliance with Minimum Closing Bid Price Requirement

Cara Therapeutics, Inc. Announces Outcome from Dose-Finding Part A of the Kourage-1 Study

First quarter 2024 earnings released: US$0.56 loss per share (vs US$0.49 loss in 1Q 2023)

Cara Therapeutics, Inc. to Report Q1, 2024 Results on May 13, 2024

Cara Therapeutics, Inc., Annual General Meeting, Jun 04, 2024

Full year 2023 earnings released: US$2.19 loss per share (vs US$1.59 loss in FY 2022)

Cara Therapeutics, Inc. to Report Q4, 2023 Results on Mar 04, 2024

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Receives A Non-Compliance Notice from the Nasdaq Stock Market

Cara Therapeutics, Inc. Prioritizes Late-Stage Notalgia Paresthetica Program

Cara Therapeutics, Inc. Announces Outcome from Dose- Finding Part A of the KIND 1 Study Evaluating Oral Difelikefalin for Mod Moderate-To-Severe Pruritus in Patients with Atopic Dermatitis

New major risk - Financial position

Third quarter 2023 earnings released: US$0.52 loss per share (vs US$0.43 loss in 3Q 2022)

Cara Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.58 loss per share (vs US$0.078 loss in 2Q 2022)

Cara Therapeutics, Inc. Appoints Helen M. Boudreau as Member of Board and Audit Committee

Cara Therapeutics, Inc. Appoints Helen M. Boudreau to Board of Directors

Cara Therapeutics, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announces England’s National Institute for Health and Care Excellence has Recommended Kapruvia

First quarter 2023 earnings released: US$0.49 loss per share (vs US$0.52 loss in 1Q 2022)

Full year 2022 earnings released: US$1.59 loss per share (vs US$1.74 loss in FY 2021)

Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine

Third quarter 2022 earnings released: US$0.43 loss per share (vs US$0.02 loss in 3Q 2021)

Cara Therapeutics Announces Appointment of Lisa Von Moltke, M.D., to Its Board of Directors

Cara Therapeutics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA®) Injection New Drug Application Has Been Submitted in Japan

Key Executive recently sold €111k worth of stock

Cara Therapeutics, Inc Appoints Ryan Maynard as Principal Financial Officer and Principal Accounting Officer

Cara Therapeutics Presents Late-Breaking Results of the KOMFORT Phase 2 Trial of Oral Difelikefalin for Pruritus in Notalgia Paresthetica at the 31st EADV Congress

Kapruvia® Gets Approval in Switzerland with Additional Regulatory Decisions

Second quarter 2022 earnings released: US$0.078 loss per share (vs US$0.61 loss in 2Q 2021)

Cara Therapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Cara Therapeutics, Inc. Announces Positive Topline Results from Komfort Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Cara Therapeutics, Inc. Announces Resignation of Thomas Reilly as Chief Financial Officer, Effective on or About June 15, 2022

First quarter 2022 earnings released: US$0.52 loss per share (vs US$0.47 loss in 1Q 2021)

Vifor Fresenius Medical Care Renal Pharma (Vfmcrp) and Cara Therapeutics, Inc. Announces the European Commission Has Granted Marketing Authorization to Kapruvia

Cara Therapeutics, Inc., Annual General Meeting, Jun 02, 2022

Cara Therapeutics, Inc Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. Announce CHMP Recommend Approval of Kapruvia for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

Independent Director recently sold €115k worth of stock

Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.35 loss in 3Q 2020)

Co-Founder recently sold €261k worth of stock

Cara Therapeutics and Vifor Pharma Announce U.S. FDA Approval of Korsuva™ (Difelikefalin) Injection for the Treatment of Moderate-To-Severe Pruritus in Hemodialysis Patients

Cara Therapeutics, Inc.(NasdaqGM:CARA) dropped from Russell Microcap Growth Index

First quarter 2021 earnings released: US$0.47 loss per share (vs US$0.62 loss in 1Q 2020)

Investor sentiment deteriorated over the past week

Cara Therapeutics Announces Topline Results From KARE Phase 2 Dose-Ranging Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Cara Therapeutics and Vifor Pharma Group Announce U.S. FDA Acceptance and Priority Review of NDA for KORSUVA™ Injection in Hemodialysis Patients with Moderate-To-Severe Pruritus

Full year 2020 earnings released: EPS US$0.18 (vs US$2.49 loss in FY 2019)

Revenue beats expectations

Cara Therapeutics, Inc. to Report Q4, 2020 Results on Feb 25, 2021

New 90-day high: €17.44

New 90-day high: €13.88

Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Pruritus in Patients with Notalgia Paresthetica

Cara Therapeutics, Inc. Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus

Co-Founder recently sold €61k worth of stock

Co-Founder recently sold €95k worth of stock

Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus

Lead Independent Director recently sold €81k worth of stock

Revenue beats expectations

Third quarter 2020 earnings released: US$0.35 loss per share

マネジメント基準チェック /24